Guided Therapeutics (GTHP) Total Debt Growth (3y) (2013 - 2025)
Guided Therapeutics (GTHP) Total Debt Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 26.30% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 4.07% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 4.70% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 6.99% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 0.11% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 2.61% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -0.32% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 5.42% |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | -32.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -32.13% |
| Sep 30, 2025 | -70.12% |
| Jun 30, 2025 | -22.93% |
| Mar 31, 2025 | 14.94% |
| Dec 31, 2024 | -58.96% |
| Sep 30, 2024 | 13.69% |
| Jun 30, 2024 | 10.26% |
| Mar 31, 2024 | -66.13% |
| Sep 30, 2023 | 23.49% |
| Jun 30, 2023 | -1.21% |
| Mar 31, 2023 | -65.95% |
| Dec 31, 2022 | -49.43% |
| Sep 30, 2022 | 18.21% |
| Jun 30, 2022 | -48.26% |
| Mar 31, 2022 | -67.02% |
| Dec 31, 2021 | 25.99% |
| Sep 30, 2021 | -21.05% |
| Jun 30, 2021 | -3.04% |
| Mar 31, 2021 | -11.94% |
| Dec 31, 2020 | -31.41% |